Intercept loses Ocaliva FDA full approval bid in rare liver disease
Intercept’s US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease ...
Ovintiv to buy Montney assets in $2.37B deal, sell Uinta assets for $2B
Ovintiv (NYSE:OVV) said Thursday it agreed to acquire 109K net acres and 70K boe/day of production in Alberta's Montney shale ...
Reuters12h
US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder
Nov 13 (Reuters) - The U.S. Food and Drug Administration approved PTC Therapeutics' (PTCT.O), opens new tab gene therapy to ...
Business Insider1d
Stifel Nicolaus Keeps Their Buy Rating on OmniAb (OABI)
Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on OmniAb (OABI – Research Report) today and set a price target of $11.00. The company’s shares closed yesterday at $4.49. Willey covers ...
Business Insider1d
Opus Genetics reinstated with a Buy at H.C. Wainwright
H.C. Wainwright reinstated coverage of Opus Genetics (IRD) with a Buy rating and $8 price target The firm believes inherited retinal disease development presents an efficient path to concise studies ...